- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT03257189
Evaluation of Performance, Usability, and Reliability of a Novel Device for Continuous Collection of Physiological Data
A Study to Evaluate the Performance, Usability, and Reliability of a Novel Device for Continuous Collection of Physiological Data in Healthcare and Remote Settings
Study objective: The primary objective of the clinical investigation is to evaluate the accuracy of BioStamp nPoint system algorithm measurements.
Study design: A single-site, non-significant risk, open-label, prospective non-randomized clinical investigation designed to validate the accuracy of the various physiological parameters that the Wearable Sensor Patches acquire and the system processes.
Aperçu de l'étude
Statut
Les conditions
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Ohio
-
Cincinnati, Ohio, États-Unis, 45212
- CTI Clinical Research Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Male or female volunteers, at least 18 years of age at the time of screening visit;
- Fluent in English;
- The subject is willing to comply with the protocol specified evaluations;
- Subject is willing and cognitively able to sign informed consent
Exclusion Criteria:
- Pregnancy;
- Positive urine drug screen
- History of active (clinically significant) skin disorders;
- History of allergic response to silicones or adhesives;
- Subjects with electronic implants of any kind (e.g. pacemaker)
- History of sleep disorders or self-reported insomnia or other sleep conditions;
- Broken, damaged or irritated skin or rashes near the sensor application sites;
- Subjects that are MC10 employees or shareholders, or a spouse or child of an MC10 employee or shareholder;
- Subjects who are physically or cognitively unable to normally perform activities of daily living, assessed at the discretion of the investigator.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Autre
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Autre: Single Arm
This single arm consists of all subjects which will interact with the device under investigation as well as comparator devices. This includes the Physiological signal monitor intervention, Heart rate and heart rate variability comparison device intervention, Respiration rate comparison device intervention, and Activity classification intervention. |
Wireless remote monitoring system intended for use by researchers and healthcare professionals for continuous collection of physiological data in home and healthcare settings.
FDA cleared reference device that monitors heart rate and heart rate variability in subjects
FDA cleared reference device that monitors respiration rate in subjects
Visual annotation of subject posture and other activities used for reference
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Accuracy of Heart Rate Measured in Beats Per Minute Compared to Reference Device
Délai: 2 days after informed consent
|
Heart rate as measured by the subject device in beats per minute will be compared to the reference device.
The Mean Absolute Error (MAE) between measurements from each device is presented.
|
2 days after informed consent
|
|
Accuracy of Heart Rate Variability Measured by Root Mean Square of Successive Differences (HRV RMSSD) Compared to the Reference Device
Délai: 2 days after informed consent
|
Heart Rate Variability RMSSD is measured by the subject device determined by root mean square of successive differences in neighboring RR intervals and will be compared to the reference device.
The Mean Absolute Error (MAE) between measurements from each device is presented.
|
2 days after informed consent
|
|
Accuracy of Heart Rate Variability Measured by Low Frequency Content to High Frequency Content Ratio (HRV Ratio) Compared to the Reference Device
Délai: 2 days after informed consent
|
HRV Ratio as measured by the subject device determined by low frequency content to high frequency content ratio (HRV Ratio) in beats per minute will be compared to the reference device.
The Mean Absolute Error (MAE) between measurements from each device is presented.
|
2 days after informed consent
|
|
Accuracy of Respiration Rate Measured in Breaths Per Minute Compared to the Reference Device
Délai: 2 days after informed consent
|
Respiration rate as measured by the subject device in breaths per minute will be compared to the reference device.
The Mean Absolute Error (MAE) between measurements from each device is presented.
|
2 days after informed consent
|
|
Accuracy of Activity Classification as Compared to Visual Annotation
Délai: 2 days after informed consent
|
The device under test will classify a subjects activity into sleeping, standing, sitting, lying, walking and other activities as the subject performs various predefined activities, which are annotated by an observer.
The device's Activity Classification will be compared to the observer's annotation.
The percentage of correct classifications by the device against indicated visual observation is presented.
The percent correct is not a per subject average, but is the percentage of all activity classifications which were correct when compared to ground truth observation.
|
2 days after informed consent
|
|
Accuracy of Step Count Compared to an Observer's Manual Count
Délai: 2 days after informed consent
|
The number of steps reported by the device under test during a 6 minute walk test will be compared to an observer's manual count of the number of steps taken.
|
2 days after informed consent
|
|
Accuracy of Sleep Onset Time (Hours, Minutes, and Seconds), Sleep Wake Time (Hours, Minutes, and Seconds) as Compared to an Observer's Visual Annotation
Délai: 2 days after informed consent
|
Sleep onset and wake times as reported by the device under test will be compared to an observer's visual annotation of the sleep onset and wake times.
The Mean Absolute Error (MAE) between times as indicated by the device and observed times is presented.
|
2 days after informed consent
|
|
Accuracy of Posture Classification as Compared to Visual Annotation
Délai: 2 days after informed consent
|
The device under test will classify a subjects activity into sleep posture, standing posture, and sitting posture as the subject performs various predefined activities, which are annotated by an observer.
The device's Posture Classification will be compared to the observer's annotation.
The percentage of correct classifications by the device against indicated visual observation is presented.
The percent correct is not a per subject average, but is the percentage of all posture classifications which were correct when compared to ground truth observation.
|
2 days after informed consent
|
|
Number of Sensors That Remained Sufficiently Adhered to Subjects for 24 Hours as Assessed by a 5 Point Scale
Délai: 2 days after informed consent
|
The level of sensor adhesion will be assessed by a 5 point scale (0- sensor is greater than or equal to 90% of sensor adhered, 4-sensor completely detached from subject).
Sensors receiving scores of 0 and 1 will be determined to have acceptable adhesion, while scores of 2, 3, and 4 will be considered unacceptable adhesion.
The percentage of sensors which had acceptable adhesion at sensor removal is presented.
|
2 days after informed consent
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Autres numéros d'identification d'étude
- MC10-PTL-103
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Normales saines
-
AstraZenecaParexelComplété
-
University of Wisconsin, MadisonComplété
-
Lincoln University CollegeComplété
-
Mahidol UniversityComplété
-
NovoBliss Research Pvt LtdAmbe Phytoextracts Pvt. LtdPas encore de recrutement
-
National Institute on Aging (NIA)Recrutement
-
NovoBliss Research Pvt LtdBlossom Microbiotics LLCComplété
Essais cliniques sur Physiological signal monitor
-
St. Martin De Porress HospitalComplété
-
Washington University School of MedicineComplété
-
Dana-Farber Cancer InstituteNational Institute of Nursing Research (NINR)RetiréCancer du col de l'utérus | Cancer gynécologique | Cancer des ovaires | Cancer de la trompe de Fallope | Carcinome péritonéal primaire | Cancer de l'utérusÉtats-Unis
-
Cliniques universitaires Saint-Luc- Université...ComplétéMaladie de Parkinson | Démarche, instableBelgique
-
The University of Hong KongComplété
-
Northwestern UniversityNational Institute on Deafness and Other Communication Disorders (NIDCD)RecrutementPerte auditive, neurosensorielle | Trouble cognitif léger amnésique | Démence de type AlzheimerÉtats-Unis
-
Promedius IncRecrutement
-
Luca ValciComplété
-
UMC UtrechtComplété
-
Tidal Medical TechnologiesRecrutementPostopératoireÉtats-Unis